3-(sec-butyl)benzo[d]isoxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: 3-(sec-butyl)benzo[d]isoxazole
• 英文别名: 3-Butan-2-yl-1,2-benzoxazole
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: WJMZWYLEXZFLHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  邻羟基苯甲腈 、 2-溴丁烷 在 magnesium 、 三苯基膦 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 4.0h， 以63%的产率得到3-(sec-butyl)benzo[d]isoxazole
  参考文献：
  名称：

  一种新颖的PPh 3介导的一锅法合成3-芳基或烷基1,2-苯并异恶唑

  摘要：

  已开发出新颖，有效且简便的方案，可以将PPh 3介导的2-羟基苄腈和溴化物以良好或优异的产率转化为一系列3-芳基或烷基取代的1,2-苯并恶唑。讨论了溴化物对反应的电子和空间效应。这是第一个在Barbier-Grignard型反应中构建C–C键和杂环的示例，该步骤的特征在于，比金属催化剂一步一步回收PPh 3更为容易。

  DOI：

  10.1021/acs.orglett.7b00563

文献信息

• Uridine nucleoside derivatives, compositions and methods of use
  申请人：TUFTS UNIVERSITY

  公开号：US10544183B2

  公开（公告）日：2020-01-28

  This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.

  本公开涉及尿苷核苷衍生物、包含治疗有效量的这些核苷衍生物的组合物以及使用这些核苷衍生物或组合物治疗对P2Y6受体的配体（如激动剂）有反应的疾病的方法，例如神经元疾病，包括神经退行性疾病（如阿尔茨海默病、帕金森病）和创伤性中枢神经系统损伤、疼痛、唐氏综合征（DS）、青光眼和炎症。
• Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
  申请人：TUFTS UNIVERSITY

  公开号：US10632138B2

  公开（公告）日：2020-04-28

  This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.

  本公开涉及尿苷二磷酸（UDP）衍生物、其盐和/或原药在治疗炎症（如银屑病）和青光眼方面的用途，涉及UDP衍生物的原药、包含治疗有效量的这些UDP衍生物原药的组合物以及使用这些原药治疗各种疾病的方法，这些疾病包括，如神经元疾病，包括神经退行性疾病（如阿尔茨海默病、帕金森病）和创伤性中枢神经系统损伤、疼痛、唐氏综合征（DS）、青光眼和炎症，如牛皮癣和类风湿性关节炎。
• SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20180155296A1

  公开（公告）日：2018-06-07

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
• URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE
  申请人：Tufts University

  公开号：US20200399302A1

  公开（公告）日：2020-12-24

  This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P 2 Y 6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.